

FILE 'HOME' ENTERED AT 20:21:07 ON 18 SEP 2002

=> index chemistry polymer bioscience patents pharmacology medicine
'CHEISTRY' IS NOT A VALID FILE NAME
ENTER A FILE NAME OR (IGNORE):chemistry
'BIOSCIENCE' IS NOT A VALID FILE NAME
ENTER A FILE NAME OR (IGNORE):bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

INDEX 'AGRICOLA, ALUMINIUM, ANABSTR, AQUIRE, BABS, BIGCOMMERCE, BIOTECHNO, CABA,
CAOLD, CAPLUS, CBNB, CEABA-VTB, CEN, CERAB, CIN, COMPENDEX, CONFSCI,
COPPERLIT, CORROSION, DKILIT, ENCOMPLIT, ENCOMPLIT2, FEDRIP, GENBANK,
INSPEC, INSPHYS, INVESTTEXT, IPA, ...' ENTERED AT 20:22:09 ON 18 SEP 2002

108 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s cyclosporin and (synthesis or synthesised)

2	FILE AGRICOLA
3	FILE ANABSTR
48	FILE BAES
554	FILE BIOTECHNO
11	FILE CABA
809	FILE CAPLUS
7	FILE CBNB
2	FILE CEABA-VTB
15	FILE CEN
3	FILE CIN
1	FILE COMPENDEX
3	FILE CONFSCI
11	FILE FEDRIP
1	FILE GENBANK
16	FILE INVESTTEXT
9	FILE IPA
44	FILE JICST-EPLUS
5	FILE KCSMET
5	FILE NAPFALEFT

32 FILES SEARCHED...

1	FILE NIGSHATIC
5	FILE NTIS
216	FILE PASCAL
26	FILE PFOMT
2	FILE RAPFA
568	FILE SCISEARCH
40	FILE IFIFAT
2644	FILE USPATFULL
22	FILE USPAT2
55	FILE WFIDS
55	FILE WFINDEX
57	FILE ADISALEFTS
35	FILE ADISINSIGHT
13	FILE ADISNEWS
14	FILE BIGBUSINESS
744	FILE BIOSIS
14	FILE BIOTECHABS
14	FILE BIOTECHDS

61 FILES SEARCHED...

363	FILE CANCERLIT
3	FILE DDFB
277	FILE DDFU

```

3   FILE DRUGB
475  FILE DRUGU
1   FILE DRUGUPDATES
5   FILE EMBAL
1719 FILE EMBASE
273  FILE ESBIOBASE
4   FILE HEALSAFE
265  FILE LIFESCI
814  FILE MEDLINE
1   FILE OCCEAN
13   FILE PHAR
1   FILE PHIC
3   FILE PHIN
1   FILE SYNTHLINE
713  FILE TOXCENTER
3   FILE VETU
93 FILES SEARCHED...
4   FILE IPCI
518  FILE EUROPATFULL
11   FILE INFADOC
6   FILE PATOSEP
6   FILE PATOSWO
995  FILE PCTFULL
15   FILE NLDB

```

63 FILES HAVE ONE OR MORE ANSWERS, 108 FILES SEARCHED IN STNINDEX

L1 QUE CYCLOSPORIN AND (SYNTHESIS OR SYNTHESISED)

=> file hits			
COST IN U.S. DOLLARS	SINCE ENTRY	TOTAL	
FULL ESTIMATED COST	3.18	3.60	SESSION

FILE 'USPATFULL' ENTERED AT 20:25:42 ON 18 SEP 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'PCTFULL' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Univentio

FILE 'CAPLUS' ENTERED AT 20:25:42 ON 18 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 20:25:42 ON 18 SEP 2002

FILE 'BIOSIS' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'TOXCENTER' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 ACS

FILE 'SCISEARCH' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'BIOTECHNO' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'EUROPATFULL' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (c) 2002 WILA Verlag Muenchen (WILA)

FILE 'DRUGU' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'CANCERLIT' ENTERED AT 20:25:42 ON 18 SEP 2002

FILE 'DIFU' ACCESS NOT AUTHORIZED

FILE 'ESBIOBASE' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'LIFESCI' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 20:25:42 ON 18 SEP 2002

Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'ADISALERTS' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'WPIDS' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'BABS' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (c) 2002 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'JICST-EPLUS' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'IFIPAT' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 IFI CLAIMS (R) Patent Services (IFI)

FILE 'ADISINSIGHT' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'PROMT' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'USPAT2' ENTERED AT 20:25:42 ON 18 SEP 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CABA' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 CAB INTERNATIONAL (CABI)

FILE 'INVESTTEXT' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Thomson Financial Services, Inc. (TFS)

FILE 'CEN' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'NLDB' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'BIGBUSINESS' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOECHDS' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'ADISNEWS' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'PHAR' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 PCB Publications Ltd. (PJB)

FILE 'FEDRIP' ENTERED AT 20:25:42 ON 18 SEP 2002

FILE 'INPADOC' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 European Patent Office, Vienna (EPO)

FILE 'AGRICOLA' ENTERED AT 20:25:42 ON 18 SEP 2002

FILE 'IPA' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 American Society of Hospital Pharmacists (ASHP)

FILE 'CBNB' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (c) 2002 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'PATOSEP' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (c) 2002 WILEY Verlag Muenchen (WILA)

FILE 'PATOSWO' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (c) 2002 WILEY Verlag Muenchen (WILA)

FILE 'KOSMET' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 International Federation of the Societies of Cosmetics Chemists

FILE 'NAPEALERT' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NTIS' ENTERED AT 20:25:42 ON 18 SEP 2002

Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.

All rights reserved. (2002)

FILE 'EMBAL' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'HEALSAFE' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'DPCI' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'ANABSTER' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (c) 2002 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'CIN' ENTERED AT 20:25:42 ON 18 SEP 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DRUGB' ENTERED AT 20:25:42 ON 18 SEP 2002

COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'PHIN' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'VETU' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'CEABA-VTB' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (c) 2002 DEGHEMA &V

FILE 'RAPRA' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 RAPRA Technology Ltd.

FILE 'COMPENDEX' ENTERED AT 20:25:42 ON 18 SEP 2002
Compendex Compilation and Indexing (C) 2002
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'GENBANK' ENTERED AT 20:25:42 ON 18 SEP 2002

FILE 'NIOSHTIC' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'DRUGUPDATES' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'OCEAN' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'PHIC' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'SYNTHLINE' ENTERED AT 20:25:42 ON 18 SEP 2002
COPYRIGHT (C) 2002 Prous Science

=> s 11 and alkyl
L2 1541 FILE USPATFULL
L3 6 FILE EMBASE
L4 610 FILE PCTFULL
L5 17 FILE CAPLUS
L6 1 FILE MEDLINE
L7 4 FILE BIOSIS
L8 4 FILE TOXCENTER
L9 4 FILE SCISEARCH
L10 1 FILE BIOTECHNO
L11 283 FILE EUROPATFULL
L12 2 FILE DRUGU
L13 1 FILE CANCEPLIT
L14 0 FILE ESBIOWEB
L15 0 FILE LIFESCI
L16 2 FILE PASCAL
L17 0 FILE ADISALEERTS
L18 23 FILE WPIDS
L19 2 FILE EAES
L20 0 FILE JICST-EPLUS
L21 16 FILE IFIPAT
L22 0 FILE ADISINSIGHT
L23 1 FILE PPOMT
L24 14 FILE USPAT2
L25 0 FILE CABA
L26 1 FILE INVESTTEXT
L27 1 FILE CEN
L28 0 FILE NLDB
L29 0 FILE BIGBUSINESS
L30 0 FILE BIOTECHDS

L31 0 FILE ADISNEWS
L32 0 FILE PHAR
L33 0 FILE FEDRIP
L34 0 FILE INFADOC
L35 0 FILE AGRICOLA
L36 0 FILE IPA
L37 0 FILE CENE
L38 0 FILE PATOSEP
L39 0 FILE PATOSWO
L40 0 FILE KOSMET
L41 0 FILE NAPRALERT
L42 0 FILE NTIS
L43 0 FILE EMEAL
L44 0 FILE HEALSAFE
L45 0 FILE DPCI
L46 0 FILE ANABSTR
L47 0 FILE CIN
L48 0 FILE CONFSCI
L49 0 FILE DRUGB
L50 0 FILE PHIN
L51 0 FILE VETU
L52 0 FILE CEABA-VTB
L53 0 FILE RAPRA
L54 0 FILE COMPENDEX
L55 0 FILE GENBANK
L56 0 FILE NIOSHTIC
L57 0 FILE DRUGUPDATES
L58 0 FILE OCEAN
L59 0 FILE PHIC
L60 0 FILE SYNTHLINE

TOTAL FOR ALL FILES

L61 2534 L1 AND ALKYL

=> s 161 and (pharmaceutical (w) composition)

L62 1223 FILE USPATFULL
L63 0 FILE EMBASE
L64 524 FILE PCTFULL
L65 0 FILE CAPLUS
L66 0 FILE MEDLINE
L67 0 FILE BIOSIS
L68 0 FILE TOXCENTER
L69 0 FILE SCISEARCH
L70 0 FILE BIOTECHNO
L71 209 FILE EUFOPATFULL
L72 0 FILE DFUGU
L73 0 FILE CANCERLIT
L74 0 FILE ESBIOBASE
L75 0 FILE LIFESCI
L76 0 FILE PASCAL
L77 0 FILE ADISALEFTS
L78 4 FILE WPIDS
L79 0 FILE EAES
L80 0 FILE JICST-EPLUS
L81 10 FILE IFIPAT
L82 0 FILE ADISINSIGHT
L83 0 FILE FRCMT
L84 12 FILE USPAT2
L85 0 FILE CABA
L86 0 FILE INVESTTEXT
L87 0 FILE CEN
L88 0 FILE NLISB
L89 0 FILE BIGBUSINESS
L90 0 FILE BICTECHDS
L91 0 FILE ADISNEWS

L92 0 FILE PHAR
L93 0 FILE FEDFIP
L94 0 FILE INPADOC
L95 0 FILE AGRICOLA
L96 0 FILE IPA
L97 0 FILE CBNB
L98 0 FILE PATOSEP
L99 0 FILE PATOSWG
L100 0 FILE KOSMET
L101 0 FILE NAPRALERT
L102 0 FILE NTIS
L103 0 FILE EMBAL
L104 0 FILE HEALSAFE
L105 0 FILE DPTI
L106 0 FILE ANABSTR
L107 0 FILE CIN
L108 0 FILE CONFSCI
L109 0 FILE DFUGB
L110 0 FILE PHIN
L111 0 FILE VETU
L112 0 FILE CEABA-VTB
L113 0 FILE FAFFA
L114 0 FILE COMPENDEX
L115 0 FILE GENBANK
L116 0 FILE NIOSHTIC
L117 0 FILE DFUGUPDATES
L118 0 FILE OCEAN
L119 0 FILE PHIC
L120 0 FILE SYNTHLINE

TOTAL FOR ALL FILES

L121 1982 L61 AND (PHARMACEUTICAL (W) COMPOSITION)

=> s 1121 and MeBmt

L122 30 FILE USPATFULL
L123 0 FILE EMBASE
L124 1 FILE PCTFULL
L125 0 FILE CAPLUS
L126 0 FILE MEDLINE
L127 0 FILE BIOSIS
L128 0 FILE TOXCENTER
L129 0 FILE SCISEARCH
L130 0 FILE BIOTECHNO
L131 7 FILE EUFOPATFULL
L132 0 FILE DFUGU
L133 0 FILE CANCERLIT
L134 0 FILE ESBIORASE
L135 0 FILE LIFESCI
L136 0 FILE PASCAL
L137 0 FILE ADISALERTS
L138 0 FILE WFIDS
L139 0 FILE BAES
L140 0 FILE JICST-EPLUS
L141 0 FILE IFIPAT
L142 0 FILE ADISINSIGHT
L143 0 FILE PFCMT
L144 0 FILE USPATE
L145 0 FILE CABA
L146 0 FILE INVESTTEXT
L147 0 FILE CEN
L148 0 FILE NLDE
L149 0 FILE BICEBUSINESS
L150 0 FILE BIOTECHNS
L151 0 FILE ADISNEWS
L152 0 FILE PHAR

L153 0 FILE FEDRIP
L154 0 FILE INPADOC
L155 0 FILE AGRICOLA
L156 0 FILE IPA
L157 0 FILE CBNB
L158 0 FILE PATOSEP
L159 0 FILE PATOSWO
L160 0 FILE KOSMET
L161 0 FILE NAPPAALERT
L162 0 FILE NTIS
L163 0 FILE EMBAL
L164 0 FILE HEALSAFE
L165 0 FILE DPCI
L166 0 FILE ANABSTR
L167 0 FILE CIN
L168 0 FILE CONFSCI
L169 0 FILE DEBUGB
L170 0 FILE PHIN
L171 0 FILE VETU
L172 0 FILE CEABA-VTB
L173 0 FILE RAPRA
L174 0 FILE COMPENDEX
L175 0 FILE GENBANK
L176 0 FILE NIOSHTIC
L177 0 FILE DRUGUPDATES
L178 0 FILE OCEAN
L179 0 FILE PHIC
L180 0 FILE SYNTHLINE

TOTAL FOR ALL FILES

L181 38 L121 AND MEBMT

=> d l181 1-38 ibib abs

L181 ANSWER 1 OF 38 USPATFULL

ACCESSION NUMBER: 2002:224588 USPATFULL
TITLE: Methods of using inhibitors of cyclophilin rotamase activity to affect neurological activity
INVENTOR(S): Steiner, Joseph P., Finksburg, MD, United States
Hamilton, Gregory S., Catonsville, MD, United States
Snyder, Solomon H., Baltimore, MD, United States
PATENT ASSIGNEE(S): Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

US 6444643	BI	20020903
US 1999-321762		19990528 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-560635, filed on 20 Nov 1995, now abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Kunz, Gary L.

ASSISTANT EXAMINER: Gucker, Stephen

LEGAL REPRESENTATIVE: Howrey Simon Arnold & White, LLP

NUMBER OF CLAIMS: 6

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)

LINE COUNT: 923

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the method of using neurotrophic cyclophilin inhibitor compounds having an affinity for cyclophilin-type immunophilins as inhibitors of the enzyme activity associated with

immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 3 OF 38 USPATFULL
ACCESSION NUMBER: 2001:8197 USPATFULL
TITLE: Synthetic transcriptional modulators and uses thereof
INVENTOR(S): Verdine, Gregory L., Lexington, MA, UNITED STATES
Nyanguile, Origene, Gaithersburg, MD, UNITED STATES
PATENT ASSIGNEE(S): President and Fellows of Harvard College (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004195	A1	20020110
APPLICATION INFO.:	US 2000-751309	A1	20001229 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-208057, filed on 9 Dec 1998, GRANTED, Pat. No. US 6193965 Continuation-in-part of Ser. No. US 1997-987912, filed on 9 Dec 1997, GRANTED, Pat. No. US 6153383		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FOLEY, HOAG & ELIOT, LLP, PATENT GROUP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Page(s)		
LINE COUNT:	3196		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel synthetic transcriptional modulators having at least one selected ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 3 OF 38 USPATFULL
ACCESSION NUMBER: 2001:202601 USPATFULL
TITLE: Regulated apoptosis
INVENTOR(S): Crabtree, Gerald, Woodside, CA, United States
Schreiber, Stuart, Boston, MA, United States
Spencer, David, Houston, TX, United States
Wandless, Thomas, Palo Alto, CA, United States
Belshaw, Peter, Somerville, MA, United States
Ho, Steffan N, San Diego, CA, United States
PATENT ASSIGNEE(S): Board of Trustees of Leland Stanford Junior University, Stanford, CA, United States (U.S. corporation)
President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6316418	B1	20011113
APPLICATION INFO.:	US 1993-302629		19990430 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-87811, filed on 29 May 1993, now patented, Pat. No. US 6054436 Continuation of Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266 Continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned Continuation-in-part of Ser. No. US 1993-23499, filed on 16 Jul 1993, now abandoned, said Ser. No. US 179143 And Ser. No. US 302629		

Continuation-in-part of Ser. No. US 1994-196043, filed on 11 Feb 1994, now abandoned Continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned Continuation-in-part of Ser. No. US 1993-92377, filed on 16 Jul 1993, now abandoned Continuation-in-part of Ser. No. US 1993-17931, filed on 13 Feb 1993, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Schwartzman, Robert A.
LEGAL REPRESENTATIVE: Vincent, Matthew P.Ropes & Gray
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 35 Drawing Figure(s); 34 Drawing Page(s)
LINE COUNT: 4291

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L131 ANSWER 4 OF 38 USPATFULL

ACCESSION NUMBER: 2001202588 USPATFULL
TITLE: **Cyclosporin** a conjugates and uses therefor
INVENTOR(S): Rich, Daniel H., Madison, WI, United States
Solomon, Michael E., Arlington, MA, United States
PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, Madison, WI,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6316405	B1	20011113
APPLICATION INFO.:	US 1999-242724		19990222 (9)
	WO 1998-US17544		19980825
			19990222 PCT 371 date
			19990222 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-57751P	19970826 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Carlson, Karen Cochrane	
ASSISTANT EXAMINER:	Tu, Stephen	
LEGAL REPRESENTATIVE:	Leone, Esq., Joseph T.Dewitt Ross & Stevens S.C.	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2215	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are conjugates of A. β -binding peptides and CsA analogs and conjugates of A. β -binding peptides and FK506 Binding Peptide inhibitors. These conjugates chemically induce dimerization of either cyclophilin or FK506 Binding Peptide with A. β . peptide, a major component of amyloid plaques found in neurological disorders such as Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis. The conjugates are useful in the treatment of neurological diseases involving the formation of amyloid plaques because they inhibit and/or prevent the aggregation and deposition of A. β . peptide into plaques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 5 OF 38 USPATFULL
 ACCESSION NUMBER: 2001:125731 USPATFULL
 TITLE: Non-Immunosuppressive **cyclosporins** and their use in the prevention and treatment of HIV infection
 INVENTOR(S): Rich, Daniel H., Madison, WI, United States
 PATENT ASSIGNEE(S): Solomon, Michael E., Arlington, MA, United States
 Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6,709,577	Bl	20010807 19990304
APPLICATION INFO.:	WO 9910373		
	US 1-99-242723		19990222 (9) 19980325
	WO 1998-US17542		19990222 PCT 371 date 19990222 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-57751P	19970826 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Park, Hankyel T.	
LEGAL REPRESENTATIVE:	Leone, Esq., Joseph T. DeWitt Ross & Stevens S.C.	
NUMBER OF CLAIMS:	31	
EXEMPLIFY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	2601	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are **cyclosporin** analogs having amino acid residue substitutions at positions 1, 3, or 7 of the **cyclosporin** peptide backbone. Also disclosed are conjugates of these **cyclosporin** analogs in which an HIV protease inhibitor moiety is conjugated to the position-7 amino acid residue of the **cyclosporin**. These compounds simultaneously bind to and inhibit cyclophilin and HIV protease. The compounds have good bioavailability and potent HIV inhibitory activity. They are useful in the treatment and prevention of HIV-mediated disorders, including AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 6 OF 38 USPATFULL
 ACCESSION NUMBER: 2001:103610 USPATFULL
 TITLE: **Cyclosporin** fermentation process
 INVENTOR(S): Ko, Soo Young, London, United Kingdom
 Kobel, Hans, Basel, Switzerland
 Besemer-Hosenwirth, Brigitte, Modling, Austria
 Seebach, Dieter, Zurich, Switzerland
 Traber, René P., Basel, Switzerland
 Wenger, Roland, Riehen, Switzerland
 Bollinger, Pietro, Bottmingen, Switzerland
 PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6,255,100	Bl	20010703
APPLICATION INFO.:	US 1999-331282		19990909 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-84709, filed on 26 May 1998, now patented, Pat. No. US 5981479 Division of Ser. No. US 1995-427312, filed on 24 Apr 1995, now patented, Pat. No. US 5767069 Continuation of Ser. No. US 1994-2312795, filed on 25 Apr 1994, now abandoned Continuation of Ser. No. US 1993-57067, filed on 3 May 1993, now abandoned Continuation of Ser. No. US		

1991-785959, filed on 31 Oct 1991, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1990-23859	19901102
	GB 1990-23970	19901105
	GB 1990-23971	19901105
	GB 1990-23972	19901105
	GB 1991-16836	19910805
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Wessendorf, T. D.	
LEGAL REPRESENTATIVE:	Lopez, Gabriel	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	309	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been found that nonimmunosuppressive, cyclophilin-binding **cyclosporins** are useful in the treatment and prevention of AIDS and AIDS-related disorders. Such **cyclosporins** include novel Cyclosporin derivatives modified at the 4- and/or 5-positions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 7 OF 38 USPATFULL
ACCESSION NUMBER: 2001:18213 USPATFULL
TITLE: Synthetic transcriptional modulators and uses thereof
INVENTOR(S): Verdine, Gregory L., Lexington, MA, United States
Nyanguile, Origene, Gaithersburg, MD, United States
PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6183965	B1	20010206
APPLICATION INFO.:	US 1998-208057		19981209 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-987912, filed on 9 Dec 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schwartzman, Robert A.		
LEGAL REPRESENTATIVE:	Foley, Hoag & Eliot, LLP, Clauss, Isabelle M., Vincent, Matthew P.		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	3213		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel synthetic transcriptional modulators having at least one selected ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 8 OF 38 USPATFULL
ACCESSION NUMBER: 2000:174415 USPATFULL
TITLE: Regulated transcription of targeted genes and other biological events
INVENTOR(S): Chakrtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States

PATENT ASSIGNEE(S): Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Cambridge, MA, United States
Board of Trustees of Leland Stanford Jr. University,
Stanford, CA, United States (U.S. corporation)
President and Fellows of Harvard College, Cambridge,
MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6166787		20001226
APPLICATION INFO.:	US 1998-87647		19980529 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-479396, filed on 7 Jun 1995, now patented, Pat. No. US 5930462 And a continuation-in-part of Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266 which is a continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-43499, filed on 16 Jul 1993, now abandoned, said Ser. No. US 478386 which is a division of Ser. No. US 1995-399653, filed on 14 Feb 1995, now patented, Pat. No. US 5963337 which is a continuation-in-part of Ser. No. US 1994-196043, filed on 11 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-42977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	Schwartzman, Robert		
LEGAL REPRESENTATIVE:	Berstein, David L., Hausdorff, Sharon F., Clauss, Isabelle M.		
NUMBER OF CLAIMS:	129		
EXEMPLARY CLAIM:	62		
NUMBER OF DRAWINGS:	36 Drawing Figure(s); 36 Drawing Page(s)		
LINE COUNT:	5058		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the zeta chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene. Regulated intracellular protein association with our cell permeable, synthetic ligands offers new capabilities in biological research and medicine, in particular, in gene therapy. Using gene transfer techniques to introduce our artificial receptors, one can turn on or off the signaling pathways that lead to the overexpression of therapeutic proteins by administering orally active "dimerizers" or "de-dimerizers", respectively. Since cells from different recipients can be configured to have the pathway overexpress different therapeutic proteins for use in a variety of disorders, the dimerizers have the potential to serve as "universal

drugs". They can also be viewed as cell permeable, organic replacements for therapeutic antisense agents or for proteins that would otherwise require intravenous injection or intracellular expression (e.g., the LDL receptor or the CFTR protein).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 9 OF 38 USPATFULL

ACCESSION NUMBER: 2000:160780 USPATFULL
TITLE: Synthetic transcriptional modulators and uses thereof
INVENTOR(S): Verdine, Gregory L., 91 Outlook Dr., Lexington, MA,
United States 02173
Nyanguile, Origene, 2517 Baltimore Rd. #4, Rockville,
MD, United States 20853

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 6153383 20001128
APPLICATION INFO.: US 1997-987912 19971209 (8)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schwartzman, Robert A.
LEGAL REPRESENTATIVE: Foley, Hoag & Eliot LLP, Vincent, Matthew P., Clauss,
Isabelle M.
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2897

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel synthetic transcriptional modulators having at least one selected ligand linked to at least one transcriptional modulating portion are described. The transcriptional modulators of the present invention can include a ligand linked to a chemical moiety. These transcriptional modulators can be used to selectively control gene expression and to identify components of the transcriptional machinery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 10 OF 38 USPATFULL

ACCESSION NUMBER: 2000:50686 USPATFULL
TITLE: Regulated apoptosis
INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Cambridge, MA, United States
PATENT ASSIGNEE(S): Board of Trustees of Leland S. Stanford Jr. Univ.,
Stanford, CA, United States (U.S. corporation)
President & Fellows of Harvard College, Cambridge, MA,
United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 6054436 20000425
APPLICATION INFO.: US 1998-87811 19980529 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-292537, filed on 18 Aug 1994, now patented, Pat. No. US 5834266 which is a continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned And a continuation-in-part of Ser. No. US 1994-196043, filed on 14 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a

continuation-in-part of Ser. No. US 1993-91977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned

DOCUMENT TYPE:

Utility

FILE SEGMENT:

Granted

PRIMARY EXAMINER:

Elliott, George C.

ASSISTANT EXAMINER:

Schwartzman, Robert

LEGAL REPRESENTATIVE:

Berstein, David L., Hausdorff, Sharon F., Clauss, Isabelle M.

NUMBER OF CLAIMS:

64

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

35 Drawing Figure(s); 34 Drawing Page(s)

LINE COUNT:

5061

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 11 OF 38 USPATFULL

ACCESSION NUMBER: 2000:40892 USPATFULL

TITLE: Regulated transcription of targeted genes and other biological events

INVENTOR(S):

Crabtree, Gerald R., Woodside, CA, United States

Schreiber, Stuart L., Cambridge, MA, United States

Spencer, David M., Los Altos, CA, United States

Wandless, Thomas J., Cambridge, MA, United States

Belshaw, Peter, Cambridge, MA, United States

Hs, Steffan N., San Diego, CA, United States

PATENT ASSIGNEE(S): Board of Trustees of Leland Stanford Jr. University, Stanford, CA, United States (U.S. corporation)
President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

US 6046047 20000404

US 1998-157230 19980916 (9)

PATENT INFORMATION:

APPLICATION INFO.:

RELATED APPLN. INFO.:

Continuation of Ser. No. US 1995-388653, filed on 14 Feb 1995, now patented, Pat. No. US 5869337 And a continuation-in-part of Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266 which is a continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned, said Ser. No. US 388653 which is a continuation-in-part of Ser. No. US 1994-196043, filed on 14 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned

DOCUMENT TYPE:

Utility

FILE SEGMENT:

Granted

PRIMARY EXAMINER:

Degen, Nancy

ASSISTANT EXAMINER:

Schwartzman, Robert

LEGAL REPRESENTATIVE:

Berstein, David L., Vincent, Matthew P., Clauss, Isabelle M.

NUMBER OF CLAIMS:

127

EXEMPLARY CLAIM:

65

NUMBER OF DRAWINGS:

37 Drawing Figure(s); 36 Drawing Page(s)

LINE COUNT:

4562

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the zeta chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene. Regulated intracellular protein association with our cell permeable, synthetic ligands offers new capabilities in biological research and medicine, in particular, in gene therapy. Using gene transfer techniques to introduce our artificial receptors, one can turn on or off the signaling pathways that lead to the overexpression of therapeutic proteins by administering orally active "dimerizers" or "de-dimerizers", respectively. Since cells from different recipients can be configured to have the pathway overexpress different therapeutic proteins for use in a variety of disorders, the dimerizers have the potential to serve as "universal drugs". They can also be viewed as cell permeable, organic replacements for therapeutic antisense agents or for proteins that would otherwise require intravenous injection or intracellular expression (e.g., the LDL receptor or the CFTR protein).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 12 OF 38 USPATFULL

ACCESSION NUMBER:

2000:37639 USPATFULL

TITLE:

Regulated transcription of targeted genes and other biological events

INVENTOR(S):

Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Ho, Steffan N., San Diego, CA, United States
Belshaw, Peter, Cambridge, MA, United States

PATENT ASSIGNEE(S):

Board of Trustees of Leland Stanford Jr. Univ.,
Stanford, CA, United States (U.S. corporation)
President & Fellows of Harvard College, Cambridge, MA,
United States (U.S. corporation)

NUMBER KIND DATE

----- ----- -----

PATENT INFORMATION:

US 6043083 20000328

APPLICATION INFO.:

US 1998-157753 19980916 (3)

RELATED APPLN. INFO.:

Continuation of Ser. No. US 1995-388653, filed on 14 Feb 1995, now patented, Pat. No. US 5869337 which is a continuation-in-part of Ser. No. US 1994-196043, filed on 14 Feb 1994 which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-32977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned And a continuation of Ser. No. US 1994-332597, filed on 18 Aug 1994, now

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Bernstein, David L., Vincent, Matthew P., Clauss, Isabelle M.

NUMBER OF CLAIMS: 71
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 37 Drawing Figure(s); 36 Drawing Page(s)
LINE COUNT: 4828

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta. chain of the T cell receptor (TCR)CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene. Regulated intracellular protein association with our cell permeable, synthetic ligands offers new capabilities in biological research and medicine, in particular, in gene therapy. Using gene transfer techniques to introduce our artificial receptors, one can turn on or off the signaling pathways that lead to the overexpression of therapeutic proteins by administering orally active "dimerizers" or "de-dimerizers", respectively. Since cells from different recipients can be configured to have the pathway overexpress different therapeutic proteins for use in a variety of disorders, the dimerizers have the potential to serve as "universal drugs". They can also be viewed as cell permeable, organic replacements for therapeutic antisense agents or for proteins that would otherwise require intravenous injection or intracellular expression (e.g., the LDL receptor or the CFTR protein).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 13 OF 38 USPATFULL
ACCESSION NUMBER: 2000:1861 USPATFULL
TITLE: Regulated transcription of targeted genes and other biological events
INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Cambridge, MA, United States
PATENT ASSIGNEE(S): Board of Trustees of Leland Stanford Jr. University, Stanford, CA, United States (U.S. corporation)
President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

PATENT INFORMATION:	NUMBER	KIND	DATE
	-----	-----	-----
	US 6011018		20000104

APPLICATION INFO.: US 1393-87716 13980529 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1395-388653, filed on 14 Feb 1995, now patented, Pat. No. US 5869337 which is a continuation-in-part of Ser. No. US 1394-196043, filed on 11 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1394-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1393-32977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1393-17931, filed on 12 Feb 1993, now abandoned And a continuation-in-part of Ser. No. US 1394-392597, filed on 12 Aug 1994, now patented, Pat. No. US 5834266 which is a continuation-in-part of Ser. No. US 1394-179143, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1393-93499, filed on 16 Jul 1993, now abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Elliott, George C.

ASSISTANT EXAMINER: Schwartzman, Robert

LEGAL REPRESENTATIVE: Bernstein, David L., Hausdorff, Sharon F., Vincent, Matthew P.

NUMBER OF CLAIMS: 79

EXEMPLIFY CLAIM: 1

NUMBER OF DRAWINGS: 36 Drawing Figure(s); 36 Drawing Page(s)

LINE COUNT: 4687

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the zeta chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene. Regulated intracellular protein association with our cell permeable, synthetic ligands offers new capabilities in biological research and medicine, in particular, in gene therapy. Using gene transfer techniques to introduce our artificial receptors, one can turn on or off the signaling pathways that lead to the overexpression of therapeutic proteins by administering orally active "dimerizers" or "de-dimerizers", respectively. Since cells from different recipients can be configured to have the pathway overexpress different therapeutic proteins for use in a variety of disorders, the dimerizers have the potential to serve as "universal drugs". They can also be viewed as cell permeable, organic replacements for therapeutic antisense agents or for proteins that would otherwise require intravenous injection or intracellular expression (e.g., the LDL receptor or the CFTR protein).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 14 OF 38 USPATFULL

ACCESSION NUMBER: 1399:155696 USPATFULL

TITLE: Regulated apoptosis

INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States

PATENT ASSIGNEE(S):
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Somerville, MA, United States
Board of Trustees of the Leland S. Stanford, Jr. Univ.,
Stanford, CA, United States (U.S. corporation)
President and Fellows of Harvard College, Cambridge,
MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5994313		19991130
APPLICATION INFO.:	US 1995-483893		19950607 (3)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-192537, filed on 18 Aug 1994, now patented, Pat. No. US 5834266 which is a continuation-in-part of Ser. No. US 1994-196043, filed on 14 Feb 1994, now abandoned And Ser. No. US 1994-179143, filed on 17 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned, said Ser. No. US 196043 which is a continuation-in-part of Ser. No. US 1994-179743, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Bernstein, David L., Hausdorff, Sharon F., Vincent, Matthew P.

NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Figure(s); 34 Drawing Page(s)
LINE COUNT: 4791

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L131 ANSWER 15 OF 38 USPATFULL
ACCESSION NUMBER: 1999:141886 USPATFULL
TITLE: **Cyclosporins**
INVENTOR(S): Ko, Soo Young, London, United Kingdom
Kobel, Hans, Basel, Switzerland
Besemer-Rosenwirth, Brigitte, Modling, Austria
Seebach, Dieter, Zurich, Switzerland
Traber, Rene P., Basel, Switzerland
Wenger, Roland, Riehen, Switzerland
Bollinger, Pietro, Bottmingen, Switzerland
Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5991473		19991109
APPLICATION INFO.:	US 1995-84709		19980526 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-427312, filed on 24 Apr 1995, now patented, Pat. No. US 5767069		

NUMBER	DATE
--------	------

PRIORITY INFORMATION: GB 1990-23853 19901102
GB 1990-23370 19901105
GB 1990-23371 19901105
GB 1990-23372 19901105
GB 1991-16336 19910805

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
LEGAL REPRESENTATIVE: Lopez, Gabriel, Furman, Diane E.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 341

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been found that nonimmunosuppressive, cyclophilin-binding **cyclosporins** are useful in the treatment and prevention of AIDS and AIDS-related disorders. Such **cyclosporins** include novel Cyclosporin derivatives modified at the 4- and/or 5-positions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 16 OF 38 USPATFULL
ACCESSION NUMBER: 199319001 USPATFULL
TITLE: Regulated transcription of targeted genes and other biological events
INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Balshaw, Peter, Cambridge, MA, United States
PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
Board of Trustees of Leland S. Stanford Jr. University, Stanford, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 5869337 19990209
APPLICATION INFO.: US 1995-388653 19950214 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-196043, filed on 11 Feb 1994 And Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266, each Ser. No. US which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned, said Ser. No. US 292597 which is a continuation-in-part of Ser. No. US 1994-179148, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 17931

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Vincent, Matthew P., Clauss, Isabelle M. Foley, Hoag & Eliot LLP
NUMBER OF CLAIMS: 165
EXEMPLARY CLAIM: 35
NUMBER OF DRAWINGS: 37 Drawing Figure(s); 36 Drawing Page(s)
LINE COUNT: 4716

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dimerization and oligomerization of proteins are general biological

control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the zeta chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene. Regulated intracellular protein association with our cell permeable, synthetic ligands offers new capabilities in biological research and medicine, in particular, in gene therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 17 OF 38 USPATFULL
ACCESSION NUMBER: 1998:138709 USPATFULL
TITLE: Regulated apoptosis
INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Somerville, MA, United States
PATENT ASSIGNEE(S): President & Fellows of Harvard College, Cambridge, MA,
United States (U.S. corporation)
Board of Trustees of Leland Stanford Jr. University,
Stanford, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5834266		19981110
APPLICATION INFO.:	US 1994-292597		19940818 (3)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned And Ser. No. US 1994-179748, filed on 7 Jan 1994 which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned , said Ser. No. US 179143 which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Vincent, Matthew P., Clauss, Isabelle M. Foley, Hoag & Elicit LLP

NUMBER OF CLAIMS: 235
EXEMPLARY CLAIM: 118
NUMBER OF DRAWINGS: 35 Drawing Figure(s); 34 Drawing Page(s)
LINE COUNT: 5,199

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 18 OF 38 USPATFULL
ACCESSION NUMBER: 1393:134626 USPATFULL
TITLE: Regulated transcription of targeted genes and other biological events
INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Bellshaw, Peter, Cambridge, MA, United States
PATENT ASSIGNEE(S): President & Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
Board of Trustees of Leland S. Stanford, Jr. University, Stanford, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

US 5830462		19931103
------------	--	----------

US 1995-478386		19950607 (8)
----------------	--	--------------

RELATED APPLN. INFO.:	Division of Ser. No. US 1995-388653, filed on 14 Feb 1995 And a continuation-in-part of Ser. No. US 1994-292597, filed on 13 Aug 1994 which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned, said Ser. No. US 388653 which is a continuation-in-part of Ser. No. US 1994-196043, filed on 11 Feb 1994 which is a continuation-in-part of Ser. No. US 179748 which is a continuation-in-part of Ser. No. US 92977 which is a continuation-in-part of Ser. No. US 17931
-----------------------	--

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Elliott, George C.

ASSISTANT EXAMINER: Schwartzman, Robert

LEGAL REPRESENTATIVE: Vincent, Matthew P., Clauss, Isabelle M. Foley, Hoag & Eliot LLP

NUMBER OF CLAIMS: 137

EXEMPLARY CLAIM: 34

NUMBER OF DRAWINGS: 37 Drawing Figure(s); 36 Drawing Page(s)

LINE COUNT: 4581

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the zeta chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 19 OF 38 USPATFULL

ACCESSION NUMBER: 1998:68992 USPATFULL
 TITLE: **Cyclosporins**
 INVENTOR(S): Ko, Soo Young, London, Great Britain
 Kobel, Hans, Basel, Switzerland
 Besemer-Rosenwirth, Brigitte, Mödling, Austria
 Seebach, Dieter, Zurich, Switzerland
 Traber, René P., Basel, Switzerland
 Wenger, Roland, Riehen, Switzerland
 Bollinger, Pietro, Bottmingen, Switzerland
 PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5767069		19980616
APPLICATION INFO.:	US 1995-427312		19950424 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-232795, filed on 25 Apr 1994, now abandoned which is a continuation of Ser. No. US 1993-57067, filed on 3 May 1993, now abandoned which is a continuation of Ser. No. US 1991-785959, filed on 31 Oct 1991, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1990-23859	19901103
	GB 1990-23970	19901105
	GB 1990-23971	19901105
	GB 1990-23972	19901105
	GB 1991-16836	19910803

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Achutamurthy, Pennathapura
 ASSISTANT EXAMINER: Wessendorf, T. D.
 LEGAL REPRESENTATIVE: Mathias, Marla J., McGovern, Thomas G.
 NUMBER OF CLAIMS: 6
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
 LINE COUNT: 779

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nonimmunosuppressant **cyclosporin** derivatives having cyclophilin-binding activity, for example, the compound, [Meile].sup.4 -ciclosporin, are useful in inhibiting HIV-1 replication in treating AIDS and AIDS related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 20 OF 38 USPATFULL
 ACCESSION NUMBER: 97:56636 USPATFULL
 TITLE: O-acylated **cyclosporins**
 INVENTOR(S): Boelsterli, Johann Jakob, Buus, Switzerland
 Eberle, Marcel Karl, Fiehen, Switzerland
 Naef, Reto, Fheinfelden, Switzerland
 Payne, Trevor Glyn, Berne, Switzerland
 PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5643870		19970701
APPLICATION INFO.:	US 1993-23525		19930226 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1992-4466	19920302
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Tsang, Cecilia	

ASSISTANT EXAMINER: Marshall, S. G.
LEGAL REPRESENTATIVE: Honor, Robert S., Kassenoff, Melvyn M., McGovern,
Thomas C.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 770

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A **cyclosporin** of the formula ##STR1## wherein A is a residue of the formula ##STR2## wherein R is hydrogen, C_{sub.1-3} **alkyl**, C_{sub.1-3} alkoxy or C_{sub.1-3} alkylthio; halo-substituted-C_{sub.1-3} **alkyl**, -C_{sub.1-3} alkoxy or -C_{sub.1-3} alkylthio; hydroxy-substituted-C_{sub.1-3} **alkyl**, -C_{sub.2-3} alkoxy or -C_{sub.2-3} alkylthio; or amino or mono- or di-(C_{sub.1-2} **alkyl**)-amino,

X is oxygen or sulphur,

--x--y-- is --CH.dbd.CH-- (trans) or --CH.sub.2 --CH.sub.2 --,

B is --alpha.Abu-, -Val-, -Thr- or -Nva- and

Q is -(D)Ala-; -(D)Ser; -[O-(2-hydroxyethyl)(D)Ser]-; or -[O-acyl(D)Ser]- or -[O-(2-acyloxyethyl)(D)Ser]-

in which the acyl residue is physiologically hydrolysable and acceptable, are useful in the topical treatment of asthma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 21 OF 38 USPATFULL
ACCESSION NUMBER: 96:50887 USPATFULL
TITLE: **Cyclosporins** and their use as pharmaceuticals
INVENTOR(S): Bollinger, Pietro, Bottmingen, Switzerland
Bolsterli, Johann J., Buus, Switzerland
Payne, Trevor G., Bern; all of, Switzerland
PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5525590		19960611
APPLICATION INFO.:	US 1994-337346		19941110 (S)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-67274, filed on 24 May 1993, now abandoned which is a continuation of Ser. No. US 1992-874676, filed on 27 Apr 1992, now abandoned which is a continuation of Ser. No. US 1991-704758, filed on 23 May 1991, now abandoned which is a continuation of Ser. No. US 1988-208422, filed on 17 Jun 1988, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1987-14090	19870617
	GB 1987-14093	19870617
	GB 1987-14098	19870617
	GB 1987-14100	19870617
	GB 1987-14115	19870617
	GB 1987-14118	19870617
	GB 1987-14119	19870617
	GB 1987-14125	19870617

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Russel, Jeffrey E.
LEGAL REPRESENTATIVE: Honor, Robert S., Kassenoff, Melvyn M., McGovern, Thomas C.
NUMBER OF CLAIMS: 5

EXEMPLARY CLAIM:

1

LINE COUNT:

2011

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Cyclosporins** wherein the residue at the 1-position (typically -MeBmt- or -dihydro-MeBmt-) is 3'-O-acylated or 3'-oxo or -C.sub.1-4 alkoxyimino substituted, or wherein the residue at the 2-position is .beta.-O-acyl or .beta.-oxo substituted, or wherein the residue at the 2 position is -Ile-, or wherein the residue at the 11-position is -MeAla-, -MeIle- or -MeAlloIle- as well as various naturally occurring **cyclosporins**/dihydro-derivatives thereof, are useful in reversing resistance to chemotherapy, in particular resistance to cytostatic or anti-neoplastic therapy. Various of these **cyclosporins** and intermediates for their production are novel. Intermediates wherein the residue (e.g. -MeBmt-, -dihydro-MeBmt- etc.) at the 1-position is 8'-alkoxy or 7'-desmethyl-7'-hydrocarbyl substituted are novel and useful as immunosuppressants, anti-inflammatory and anti-parasitic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 22 OF 38 USPATFULL

ACCESSION NUMBER:

93:57009 USPATFULL

TITLE:

Immunosuppressive fluorinated **cyclosporin** analogs

INVENTOR(S):

Durette, Philippe L., New Providence, NJ, United States
Pessolano, Arsenio A., Colonia, NJ, United States

Kollonitsch, Janos, Westfield, NJ, United States

PATENT ASSIGNEE(S):

Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:

US 5027467 19930713

APPLICATION INFO.:

US 1991-693783 19910429 (7)

RELATED APPLN. INFO.:

Continuation of Ser. No. US 1989-298712, filed on 19 Jan 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-81255, filed on 3 Aug 1987, now abandoned

DOCUMENT TYPE:

Utility

FILE SEGMENT:

Granted

PRIMARY EXAMINER:

Chan, Y. Christina

LEGAL REPRESENTATIVE:

Panzer, Curtis C., Speer, Raymond M.

NUMBER OF CLAIMS:

2

EXEMPLARY CLAIM:

1

LINE COUNT:

1023

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New immunosuppressive **cyclosporin** analogs are disclosed having one or more fluorinated amino acids. These analogs may also have a "C-9 amino acid" wherein the double bond is replaced by a heteroatom such as sulfur or oxygen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 23 OF 38 USPATFULL

ACCESSION NUMBER:

93:42149 USPATFULL

TITLE:

Synthesis of novel immunosuppressive **cyclosporin** analogs with modified amino acids at position-3

INVENTOR(S):

Patchett, Arthur A., Westfield, NJ, United States

Taub, David, Metuchen, NJ, United States

Goegelman, Robert T., Linden, NJ, United States

PATENT ASSIGNEE(S):

Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 5214130 19930525
 APPLICATION INFO.: US 1991-744039 19910812 (7)
 RELATED APPLN. INFO.: Division of Ser. No. US 1990-485920, filed on 27 Feb
 1990, now patented, Pat. No. US 5122511
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Lee, Lester L.
 ASSISTANT EXAMINER: Davenport, A. M.
 LEGAL REPRESENTATIVE: Panzer, Curtis C., Speer, Raymond M.
 NUMBER OF CLAIMS: 6
 EXEMPLARY CLAIM: 1
 LINE COUNT: 637

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New immuno-suppressive **cyclosporin** analogs are disclosed
consisting of [dehydro-Ala].sup.8 **cyclosporins** and derived
therefrom **cyclosporins** having a sulfur containing amino acid
at position-8.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 24 OF 38 USPATFULL
 ACCESSION NUMBER: 92:42045 USPATFULL
 TITLE: Immunosuppressive **cyclosporin** analogs with
modified amino acids at position-8
 INVENTOR(S): Patchett, Arthur A., Westfield, NJ, United States
 Taub, David, Metuchen, NJ, United States
 Goegelman, Robert T., Linden, NJ, United States
 PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5122511		19920616
APPLICATION INFO.:	US 1990-485920		19900227 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lee, Lester L.		
ASSISTANT EXAMINER:	Davenport, A. M.		
LEGAL REPRESENTATIVE:	Panzer, Curtis C., Pfeiffer, Hesna J.		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
LINE COUNT:	670		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New immuno-suppressive **cyclosporin** analogs are disclosed
consisting of [dehydro-Ala].sup.8 **cyclosporins** and derived
therefrom **cyclosporins** having a sulfur containing amino acid
at position-8.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 25 OF 38 USPATFULL
 ACCESSION NUMBER: 92:42742 USPATFJLL
 TITLE: **Cyclosporin** peptolides having an
.alpha.-hydroxycarboxylic acid at position 8
 INVENTOR(S): Dreyfuss, Michael M., Basel, Switzerland
 Schreier, Max H., Basel, Switzerland
 Tscherter, Hans, Allschwil, Switzerland
 PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5116816		19920506
APPLICATION INFO.:	US 1988-209680		19880620 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1987-2317 CH 1987-2517	19870619 19870702
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Chan, Christina	
LEGAL REPRESENTATIVE:	Sharkin, Gerald D., Honer, Robert S., McGovern, Thomas O.	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1,9	
LINE COUNT:	511	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cyclic peptolides having the structure of a **cyclosporin** in which one amide linkage is replaced by an ester linkage are obtained by fermentation of fungal strains of the genus *Cylindrotrichum* Bonorden, or by cyclization of a hydroxy-undecapeptide. The cyclic peptolides have immunosuppressive, anti-inflammatory and anti-parasitic properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 26 OF 38 USPATFULL
 ACCESSION NUMBER: 80:25853 USPATFULL
 TITLE: Novel 6-position **cyclosporin** analogs as non-immunosuppressive antagonists of **cyclosporin** binding to cyclophilin
 INVENTOR(S): Dumont, Francis J., Rahway, NJ, United States
 Murette, Philippe L., New Providence, NJ, United States
 Pessolano, Arsenio A., Colonia, NJ, United States
 Boger, Joshua S., Westfield, NJ, United States
 Sigal, Nolan H., Westfield, NJ, United States
 PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4914188		19900403
APPLICATION INFO.:	US 1987-121827		19871116 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lee, Lester L.		
ASSISTANT EXAMINER:	Chan, Christina		
LEGAL REPRESENTATIVE:	Diprima, Joseph F., North, Robert J., Panzer, Curtis C.		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
LINE COUNT:	691		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel **cyclosporin** analogs containing a MeAla or MeAku residue at the 6-position of the cyclic undecapeptide have been synthesized and found unexpectedly to exhibit antagonistic activity toward **cyclosporin** A binding to its cytosolic protein receptor, cyclophilin, without being immunosuppressive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 27 OF 38 USPATFULL
 ACCESSION NUMBER: 88:59156 USPATFULL
 TITLE: Novel **cyclosporins**
 INVENTOR(S): Seebach, Dieter, Zurich, Switzerland
 PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4771122		19880913
APPLICATION INFO.:	US 1987-103990		19871001 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1986-837434, filed on 7 Mar 1986, now patented, Pat. No. US 4703033

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1985-11029	19850501
	GB 1985-6230	19850511
	GB 1986-2370	19860131
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Phillips, Delbert F.	
LEGAL REPRESENTATIVE:	Sharkin, Gerald D., Honor, Robert S., McGovern, Thomas O.	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1157	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Cyclosporins e.g. of formula II ##STR1## in which X is -MeBmt- or -dihydro-MeBmt- and	
	Y is -.alpha.Abu-, -Thr-, -Val- or -Nva-,	

wherein the residue at the 3-position, i.e. the residue Z in formula II, is an optically active, .alpha.-N-methylated .alpha.-amino acid residue of the (D)-configuration, possess pharmaceutical, in particular immuno-suppressive, anti-inflammatory and anti-parasitic activity, Intermediate cyclosporin poly-anions having a de-protonated sarcosyl residue at the 3-position, e.g. polyanions of cyclosporins of formula II above wherein X and Y have the meanings given above and Z is -Sar-, in which the said residue Z is de-protonated, are also novel and part of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 28 OF 38 USPATFULL
ACCESSION NUMBER: 88:52079 USPATFULL
TITLE: Novel cyclosporins
INVENTOR(S): Wenger, Poland, Riehen, Switzerland
PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4764503		19880816
APPLICATION INFO.:	US 1987-49746		19870513 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1986-932760, filed on 19 Nov 1986, now abandoned which is a continuation of Ser. No. US 1985-713259, filed on 19 Mar 1985, now abandoned		

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Phillips, Delbert F.
LEGAL REPRESENTATIVE:	Sharkin, Gerald D., Honor, Robert S., McGovern, Thomas O.
NUMBER OF CLAIMS:	6
EXEMPLARY CLAIM:	1
LINE COUNT:	888

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cyclosporins wherein the amino acid residue at the 8-position is a (D)-acyloxy-.alpha.-amino acid residue, typically of formula ##STR1## wherein X=-MeBmt- or --dihydro--MeBmt--, Y=-.alpha.Abu--, --Ala--, --Thr--, --Val-- or --Nva--, Z=-Val-- or --Nva-- and Q=R.sub.1 --CO--O--CH(R.sub.2)--CH(CO--)--NH-- wherein R.sub.1 =H, C.sub.1-4 alkyl or phenyl and R.sub.2 =H or CH.sub.3, possess immuno-suppressive, anti-inflammatory and anti-parasitic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 29 OF 38 USPATFULL
ACCESSION NUMBER: 87:75000 USPATFULL
TITLE: Novel **cyclosporins**
INVENTOR(S): Seebach, Dieter, Zurich, Switzerland
PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4703033		19871027
APPLICATION INFO.:	US 1986-837434		19860307 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1985-6230	19850311
	GB 1985-11029	19850501
	GB 1986-2370	19860131
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Phillips, Delbert R.	
LEGAL REPRESENTATIVE:	Sharkin, Gerald D., Honor, Robert S., McGovern, Thomas O.	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1262	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Cyclosporins** e.g. of formula II ##STR1## in which X is -
MeBmt- or -dihydro-MeBmt- and

Y is -alpha.Abu-, -Thr-, -Val- or -Nva-,

wherein the residue at the 3-position, i.e. the residue Z in formula II, is an optically active, .alpha.-N-methylated .alpha.-amino acid residue of the (D)-configuration, possess pharmaceutical, in particular immunosuppressive, anti-inflammatory and anti-parasitic activity. Intermediate **cyclosporin** poly-anions having a de-protonated sarcosyl residue at the 3-position, e.g. polyanions of **cyclosporins** of formula II above wherein X and Y have the meanings given above and Z is -Sar-, in which the said residue Z is de-protonated, are also novel and part of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 30 OF 38 USPATFULL
ACCESSION NUMBER: 87:6447 USPATFULL
TITLE: Novel **cyclosporins**
INVENTOR(S): Wenger, Roland, Riehen, Switzerland
Traber, Rene P., Basel, Switzerland
Kobel, Hans, Basel, Switzerland
Hofmann, Hans, Ettingen, Switzerland
PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4639434		19870127
APPLICATION INFO.:	US 1985-713429		19850319 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1984-7613	19840323
	GB 1984-11922	19840510
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Phillips, Delbert R.	

LEGAL REPRESENTATIVE: Sharkin, Gerald L., Henor, Robert S., McGovern, Thomas J.

NUMBER OF CLAIMS: 6

EXEMPLARY CLAIM: 1

LINE COUNT: 980

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Cyclosporins** wherein the amino acid residue at the β -position is a (D)-acyloxy- α -amino acid residue, typically of formula ##STR1## wherein X=-MeBmt- or -dihydro-MeBmt-, Y=- α .Abu-, -Ala-, -Thr-, -Val- or -Nva-, Z=-Val- or -Nva- and Q=R.sub.1 --CO--O--CH(R.sub.2)--CH(CO--)--NH--wherein R.sub.1 =H, C.sub.1-4 alkyl or phenyl and R.sub.2 =H or CH.sub.3, possess immunosuppressive, anti-inflammatory and anti-parasitic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L181 ANSWER 31 OF 38 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2001072299 PCTFULL EP 200209822

TITLE (ENGLISH): TAXANE-BASED COMPOSITIONS AND METHODS OF USE

TITLE (FRENCH): COMPOSITIONS A BASE DE TAXANE ET PROCEDES D'UTILISATION

INVENTOR(S): ZHANG, Kai; SMITH, Gregory, A.; GUTIERREZ-ROCA, Jose, C.

PATENT ASSIGNEE(S): BAKER NORTON PHARMACEUTICALS, INC.; ZHANG, Kai; SMITH, Gregory, A.; GUTIERREZ-ROCA, Jose, C.

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 2001072299	A1	20011004
---------------	----	----------

DESIGNATED STATES AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US9382 A 20010323

PRIORITY INFO.: US 2000-60/191,802 200009324

ABEN Disclosed are taxane-based compositions and methods of using the same to achieve target blood levels of a taxane in a mammal, e.g., to treat taxane-responsive malignant and non-malignant diseases. Compositions of the invention exhibit long-term stability and overall palatability. Also disclosed are methods for using the compositions as analytical tools for pharmacokinetic studies.

ABFR L'invention concerne des compositions a base de taxane et des procedes permettant d'utiliser ces compositions pour atteindre des concentrations sanguines cibles de taxane chez un mammifere, par exemple, pour traiter des maladies malignes et des maladies benignes. Les compositions decrites dans cette invention presentent une stabilité à long terme et une sapidité globale. L'invention concerne également des procedes permettant d'utiliser ces compositions comme outils d'analyse dans des études pharmacocinetiques.

L181 ANSWER 32 OF 38 EUROPATFULL COPYRIGHT 2002 WIWA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 577544 EUROPATFULL EW 199401 FS OS STA B

TITLE: Novel **cyclosporins** having modifications at position 1.

Neue Cyclosporine mit Modifikationen in Position-1.

Nouvelles cyclosporines modifiées en position 1.

INVENTOR(S): Boelsterli, Johann Jakob, Brunngasse 4, CH-4463 Buus, CH;

PATENT ASSIGNEE(S):
Eberle, Marcel Karl, Bahnhofstrasse 52, CH-4125 Riehen,
CH;
Naef, Reto, Marktgasse 8a, CH-4310 Rheinfelden, CH;
Payne, Trevor Glyn, Dalmazirain 26, CH-3005 Berne, CH
SANDOZ LTD., Lichtstrasse 35, CH-4002 Basel, CH, in BE,
CH, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE;
SANDOZ-PATENT-GMBH, Humboldtstrasse 3, D-79539 Loerrach,
DE, in DE;
SANDOZ-ERFINDUNGEN Verwaltungsgesellschaft m.b.H.,
Brunner Strasse 59, A-1230 Wien, AT, in AT

PATENT ASSIGNEE NO:

OTHER SOURCE:

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

DESIGNATED STATES:

PATENT INFO.PUB.TYPE:

PATENT INFORMATION:

	PATENT NO	KIND	DATE
'OFFENLEGUNGS' DATE:	EP 577544	A1	19940105
APPLICATION INFO.:	EP 1993-810113		19930222
PRIORITY APPLN. INFO.:	GB 1992-4466		19920302

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 577544 EUROPATFULL EW 199651 FS PS
TITLE: Novel **cyclosporins** having modifications at
position 1.
Neue Cyclosporine mit Modifikationen in Position 1.
Nouvelles cyclosporines modifiees en position 1.
INVENTOR(S): Boelsterli, Johann Jakob, Brunngasse 4, CH-4463 Buus,
CH;
Eberle, Marcel Karl, Bahnhofstrasse 52, CH-4125 Riehen,
CH;
Naef, Reto, Marktgasse 8a, CH-4310 Rheinfelden, CH;
Payne, Trevor Glyn, Dalmazirain 26, CH-3005 Berne, CH
PATENT ASSIGNEE(S): SANDOZ LTD., Lichtstrasse 35, 4002 Basel, CH, in BE, CH,
DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE;
SANDOZ-PATENT-GMBH, Humboldtstrasse 3, 79539 Loerrach,
DE, in DE;
SANDOZ-ERFINDUNGEN Verwaltungsgesellschaft m.b.H.,
Brunner Strasse 59, 1235 Wien, AT, in AT
PATENT ASSIGNEE NO:
OTHER SOURCE:
SOURCE:
DOCUMENT TYPE:
LANGUAGE:
DESIGNATED STATES:
PATENT INFO.PUB.TYPE:
PATENT INFORMATION:

	PATENT NO	KIND	DATE
'OFFENLEGUNGS' DATE:	EP 577544	B1	19961218
APPLICATION INFO.:	EP 1993-810113		19930222
PRIORITY APPLN. INFO.:	GB 1992-4466		19920302
REFERENCE PAT. INFO.:	EP 414632 A		US 4996193 A

L181 ANSWER 33 OF 38 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 484.81 EUROPATFULL EW 199219 FS OS STA B
 TITLE: **Cyclosporins.**
 INVENTOR(S): Ko, Soo Young, Flat 5, 42 Belsize Park Gardens, London NW3 4LY, GB;
 Kobel, Hans, Weissensteinstrasse 1, CH-4059 Basle, CH;
 Rosenwirth, Brigitte, C. Zwillinggasse 17, A-2340 Moedling, AT;
 Seebach, Dieter, Orellistrasse 3, CH-8044 Zuerich, CH;
 Traber, Rene P., Hirzbodenpark 20, CH-4052 Basle, CH;
 Wenger, Roland, Grenzacherweg 45, CH-4125 Riehen, CH;
 Bollinger, Pietro, Gustackerstrasse 56, CH-4103 Bottmingen, CH
 PATENT ASSIGNEE(S): SANDOZ LTD., Lichtstrasse 35, CH-4002 Basel, CH, in BE, CH, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE;
 SANODZ-PATENT-GMBH, Humboldtstrasse 3, W-7850 Loerrach, DE, in DE;
 SANODZ ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H., Brunner Strasse 59, A-1235 Vienna, AT, in AT 201940; 498060; 1297990
 PATENT ASSIGNEE NO:
 OTHER SOURCE: EPB1992035 EP 0484281 A2 920506
 SOURCE: Wila-EPZ-1992-H19-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veröffentlichung in Englisch
 DESIGNATED STATES: F AT; F BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
 PATENT INFO. PUB. TYPE: EPAZ EUROPÄISCHE PATENTANMELDUNG
 PATENT INFORMATION:

PATENT NO	KIND DATE
EP 484281	A2 19920506
	19910841
EP 1990-23859	19901102
GB 1990-23972	19901105
GB 1990-23970	19901105
GB 1990-23971	19901105
GB 1991-16836	19910805

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 484281 EUROPATFULL EW 199705 FS PS
 TITLE: **Cyclosporins.**
 INVENTOR(S): Ko, Soo Young, Flat 5, 42 Belsize Park Gardens, London NW3 4LY, GB;
 Kobel, Hans, Weissensteinstrasse 1, CH-4059 Basle, CH;
 Rosenwirth, Brigitte, C. Zwillinggasse 17, A-2340 Moedling, AT;
 Seebach, Dieter, Orellistrasse 3, CH-8044 Zuerich, CH;
 Traber, Rene P., Hirzbodenpark 20, CH-4052 Basle, CH;
 Wenger, Roland, Grenzacherweg 45, CH-4125 Riehen, CH;
 Bollinger, Pietro, Gustackerstrasse 56, CH-4103 Bottmingen, CH
 PATENT ASSIGNEE(S): SANDOZ LTD., Lichtstrasse 35, 4002 Basel, CH, in BE, CH, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE;
 SANODZ-PATENT-GMBH, Humboldtstrasse 3, 79539 Loerrach, DE, in DE;
 SANODZ ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H., Brunner Strasse 59, 1235 Wien, AT, in AT 201940; 498060; 1297990
 PATENT ASSIGNEE NO:
 OTHER SOURCE: EPB1997009 EP 0484281 B1 970129

SOURCE: Wila-EPS-1997-H35-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veröffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
 PATENT INFO. PUB. TYPE: EPB1 EUROPÄISCHE PATENTSCHRIFT
 PATENT INFORMATION:

	PATENT NO	KIND	DATE
'OFFENLEGUNGS' DATE:	EP 484281	B1	19970129
APPLICATION INFO.:	EP 1991-810341		19920506
PRIORITY APPLN. INFO.:	GB 1990-13359		1991030
	GB 1990-23972		19901105
	GB 1990-23970		19901105
	GB 1990-23971		19901105
	GB 1991-16336		19910805
REFERENCE PAT. INFO.:	EP 373260 A		GB 2027244 A
	US 4814323 A		

L181 ANSWER 34 OF 38 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 444897 EUROPATFULL EW 199136 FS OS STA B
 TITLE: Novel immunosuppressive **cyclosporin** analogs
 with modified amino acids at position-3.
 Neue immunsuppressive Cyclosporinanaloge mit
 modifizierten Aminosäuren in Position 3.
 Nouvelles analogues immunsuppressives de la
 cyclosporine avec des acides aminés modifiées dans la
 position 3.
 INVENTOR(S): Patchett, Arthur A., 1090 Minisink Way, Westfield, NJ
 07090, US;
 Taub, David, 54 Wistar Avenue, Metuchen, NJ 08840, US;
 Goegelman, Robert T., 437 Academy Terrace, Linden, NJ
 07036, US
 PATENT ASSIGNEE(S): MERCK & CO. INC., 126, East Lincoln Avenue P.O. Box
 2000, Rahway New Jersey 07065-0900, US
 PATENT ASSIGNEE NO: 200479
 AGENT: Thompson, John Dr. et al, Merck & Co., Inc. European
 Patent Department Terlings Park Eastwick Road, Harlow,
 Essex CM20 2QR, GB
 A2771
 OTHER SOURCE: ESP1991064 EP 0444897 A1 910904
 SOURCE: Wila-EFZ-1991-H36-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veröffentlichung in Englisch
 DESIGNATED STATES: R CH; R DE; R FR; R GB; R IT; R LI; R NL
 PATENT INFO. PUB. TYPE: EPA1 EUROPÄISCHE PATENTANMELDUNG
 PATENT INFORMATION:

	PATENT NO	KIND	DATE
'OFFENLEGUNGS' DATE:	EP 444897	A1	19910904
APPLICATION INFO.:	EP 1991-301531		19910904
PRIORITY APPLN. INFO.:	US 1990-485920		19900327

L181 ANSWER 35 OF 38 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 307077 EUROPATFULL EW 198911 FS OS STA B
 TITLE: Tetrahydrcarbazoles for the improvement of
cyclosporin therapy.

INVENTOR(S): Tetrahydrocarbazole zur Verbesserung der
 Cyclosporintherapie.
 PATENT ASSIGNEE(S): Tetrahydrocarbazoles pour une therapie avec de la
 cyclosporine.
 PATENT ASSIGNEE NO:
 AGENT: Ford-Hutchinson, Anthony W., 69 Hyde Park, Beaconsfield,
 QUE H9W 5L7, CA
 MERCK FROSST CANADA INC., 16711 Trans-Canada Highway,
 Kirkland Quebec, CA
 923570
 Hesketh, Alan, Dr. et al, European Patent Department
 Merck & Co., Inc. Terlings Park Eastwick Road, Harlow
 Essex, CM10 2QR, GB
 31763
 OTHER SOURCE: ESPI989011 EP 0307077 A1 890315
 SOURCE: Wila-EPZ-1989-H11-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veröffentlichung in Englisch
 DESIGNATED STATES: P CH; P DE; P FR; P GB; P IT; P LI; P NL
 PATENT INFO.PUB.TYPE: EPA1 EUROPÄISCHE PATENTANMELDUNG
 PATENT INFORMATION:

PATENT NO	KIND DATE
EP 307077	A1 19890315
	19890315
EP 1988-306563	19880713
PRIORITY APPLN. INFO.: US 1987-76093	19870721

L181 ANSWER 36 OF 38 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 296123 EUROPATFULL EW 198851 FS OS STA B
 TITLE: Cyclic peptolides.
 Zyklische Peptolide.
 Peptolides cycliques.
 INVENTOR(S): Dreyfuss, Michael Morris, Paradieshofstrasse 82, CH-4054
 Basle, CH;
 Schreier, Max H., Oberwilerstrasse 50, CH-4054 Basle,
 CH;
 Tscherter, Hans, Baselmattweg 191/31, CH-4123 Allschwil,
 CH;
 Wenger, Roland, Grenzacherweg 45, CH-4125 Riehen, CH
 PATENT ASSIGNEE(S): SANDOZ AG, Lichtstrasse 35, CH-4002 Basel, CH, in BE,
 CH, ES, FR, GB, GR, IT, LI, LU, NL, SE;
 SANDOZ-PATENT-GMBH, Humboldtstrasse 3, D-7850 Loerrach,
 DE, in DE;
 SANDOZ-ERFINIUNGEN Verwaltungsgesellschaft m.b.H.,
 Brunner Strasse 59, A-1235 Wien, AT, in AT
 101341; 498060; 498070
 ESPI988048 EP 0296123 A2 881221
 PATENT ASSIGNEE NO:
 OTHER SOURCE: Wila-EPZ-1988-H51-T1
 SOURCE: Patent
 DOCUMENT TYPE: Anmeldung in Englisch; Veröffentlichung in Englisch
 LANGUAGE: P AT; P BE; P CH; P DE; P ES; P FR; P GB; P GR; P IT; P
 LI; P LU; P NL; P SE
 DESIGNATED STATES: EPA1 EUROPÄISCHE PATENTANMELDUNG
 PATENT INFORMATION:

PATENT NO	KIND DATE
EP 296123	A2 19881221
	19881221
EP 1988-310408	19880615
PRIORITY APPLN. INFO.: CH 1987-2317	19870619
CH 1987-2517	19870702

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 296123 EUROPATFULL EW 199435 FS PS STA B
TITLE: Cyclic peptolides.
Szyklische Peptolide.
Peptolides cycliques.
INVENTOR(S.): Dreyfuss, Michael Morris, Paradieshofstrasse 82, CH-4054 Basle, CH;
Schreier, Max H., Cperwilerstrasse 50, CH-4054 Basle, CH;
Tscherter, Hans, Baselmatteweg 191/31, CH-4123 Allschwil, CH;
Wenger, Roland, Grenzacherweg 45, CH-4125 Riehen, CH;
Haslberger, Alexander, Dr., Prehausergasse 41, A-1130 Wien, AT
PATENT ASSIGNEE(S.): SANDOZ AG, Lichtstrasse 35, CH-4002 Basel, CH, in BE, CH, ES, FR, GB, GR, IT, LI, LU, NL, SE;
SANDOZ-PATENT-GMBH, Humboldtstrasse 3, D-79539 Lerrach, DE, in DE;
SANDOZ-EFFINDUNGEN Verwaltungsgesellschaft m.b.H., Brunner Strasse 59, A-1230 Wien, AT, in AT
201941; 498060; 498070
PATENT ASSIGNEE NO:
OTHER SOURCE: EPB1994061 EP 0296123 B1 940831
SOURCE: Willa EPS-1994-H35 T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veröffentlichung in Englisch
DESIGNATED STATES: P AT; R BE; R CH; R DE; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPÄISCHE PATENTSCHRIFT
PATENT INFORMATION:

	PATENT NO	KIND DATE
'OFFENLEGUNGS' DATE:	EP 296123	B1 19940931
APPLICATION INFO.:	EP 1988-810408	19880615
PRIORITY APPLN. INFO.:	CH 1987-2317	19870619
	CH 1987-2517	19870702
REFERENCE PAT. INFO.:	GB 2061946 A	

L181 ANSWER 37 OF 38 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 296123 EUROPATFULL EW 198851 FS OS STA B
TITLE: Cyclosporins and their use as pharmaceuticals.
Cyclosporine und deren Benutzung als Arzneimittel.
Cycloporines et leur emploi comme medicaments.
INVENTOR(S.): Bollinger, Pietro, Gustackerstrasse 56, CH-4103 Bottmingen, CH;
Eeclsterli, Johann Jakob, Brunngasse, CH-4463 Buus, CH;
Borel, Jean-Francois, Dornachweg 4, CH-4144 Arlesheim, CH;
Krieger, Manfred, Hauptstrasse 91, CH-4422 Arisdorf, CH;
Payne, Trevor Glyn, Dalmazirain 26, CH-3005 Bern, CH;
Traber, Pene P., Wilhelm-His-Strasse 11, CH-4056 Basel, CH;
Wenger, Roland, Grenzacherweg 45, CH-4125 Riehen, CH
PATENT ASSIGNEE(S.): SANDOZ AG, Lichtstrasse 35, CH-4002 Basel, CH, in BE, CH, ES, FR, GB, GP, IT, LI, LU, NL, SE;
SANDOZ-PATENT-GMBH, Humboldtstrasse 3, D-7850 Lerrach, DE, in DE;
SANDOZ-EFFINDUNGEN Verwaltungsgesellschaft m.b.H., Brunner Strasse 59, A-1235 Wien, AT, in AT
201941; 498060; 498070
PATENT ASSIGNEE NO:
OTHER SOURCE: ESP1988048 EP 0296122 A2 881221

SOURCE: Wila-EPS-1988-H51-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veröffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
 PATENT INFO.PUB.TYPE: EPA2 EUROPÄISCHE PATENTANMELDUNG
 PATENT INFORMATION:

	PATENT NO	KIND DATE
'OFFENLEGUNGS' DATE:	EP 296122	A2 19881221
APPLICATION INFO.:	EP 1988-810403	19880614
PRIORITY APPLN. INFO.:	GB 1987-14100	19870617
	GB 1987-14090	19870617
	GB 1987-14093	19870617
	GB 1987-14098	19870617
	GB 1987-14115	19870617
	GB 1987-14118	19870617
	GB 1987-14119	19870617
	GB 1987-14125	19870617

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 296122 EUOPATFULL EW 199339 FS PS STA B
 TITLE: **Cyclosporins** and their use as pharmaceuticals.
 Cyclosporine und deren Benutzung als Arzneimittel.
 Cycloporines et leur emploi comme medicaments.
 INVENTOR(S): Bollinger, Pietro, Gustackerstrasse 56, CH-4103
 Bottmingen, CH;
 Boelsterli, Johann Jakob, Brunngasse, CH-4463 Buus, CH;
 Borel, Jean-Francois, Dornachweg 4, CH-4144 Arlesheim,
 CH;
 Krieger, Manfred, Hauptstrasse 91, CH-4422 Arisdorf, CH;
 Payne, Trevor Glyn, Dalmazirain 26, CH-3005 Bern, CH;
 Traber, Rene P., Wilhelm His-Strasse 11, CH-4056 Basel,
 CH;
 Wenger, Roland, Grenzacherweg 45, CH-4125 Riehen, CH
 SANDOZ AG, Lichtstrasse 35, CH-4002 Basel, CH, in BE,
 CH, ES, FR, GB, GR, IT, LI, LU, NL, SE;
 SANDOZ-PATENT-GMBH, Humboldtstrasse 3, D-79539 Loerrach,
 DE, in DE;
 SANDOZ-ERFINDUNGEN Verwaltungsgesellschaft m.b.H.,
 Brunner Strasse 59, A-1230 Wien, AT, in AT
 201941; 498060; 498070
 PATENT ASSIGNEE(S): EPB1993051 EP 0296122 B1 930929

PATENT ASSIGNEE NO:
 OTHER SOURCE:
 SOURCE:
 DOCUMENT TYPE:
 LANGUAGE:
 DESIGNATED STATES:

PATENT INFO.PUB.TYPE: EPB1 EUROPÄISCHE PATENTSCHRIFT
 PATENT INFORMATION:

	PATENT NO	KIND DATE
'OFFENLEGUNGS' DATE:	EP 296122	B1 19930929
APPLICATION INFO.:	EP 1988-810403	19880614
PRIORITY APPLN. INFO.:	GB 1987-14100	19870617
	GB 1987-14090	19870617
	GB 1987-14093	19870617
	GB 1987-14098	19870617
	GB 1987-14115	19870617
	GB 1987-14118	19870617
	GB 1987-14119	19870617
	GB 1987-14125	19870617

REFERENCE PAT. INFO.: EP 194972 A GB 2155936 A

L181 ANSWER 38 OF 38 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 194972 EUROPATFULL EW 199231 FS PS STA B
TITLE: Novel **cyclosporins**.
Cyclosporine.
Cyclosporines.
INVENTOR(S): Seebach, Dieter, Orellistrasse 3, CH-8044 Zurich, CH
PATENT ASSIGNEE(S): Sandoz AG, Lichtstrasse 35, CH-4002 Basel, CH, in BE,
CH, FR, GB, IT, LI, LU, NL, SE;
Sandoz-PATENT-GMBH, Humboldtstrasse 3, W-7850 Loerrach,
DE, in DE;
Sandoz-ERFINDUNGEN Verwaltungsgesellschaft m.b.H.,
Brunner Strasse 59, A-1235 Wien, AT, in AT
PATENT ASSIGNEE NO: 201941; 498060; 498070
OTHEF SOURCE: EPB1992038 EP 0194972 B1 920729
SOURCE: Wila-EPS-1992-H31-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veröffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R FR; R GB; R IT; R LI; R LU; R
NL; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPÄISCHE PATENTSCHRIFT
PATENT INFORMATION:

	PATENT NO	KIND	DATE
'OFFENLEGUNGS' DATE:	EP 194972	B1	19920729
APPLICATION INFO.:	EP 1986-810112		19860917
PRICORITY APPLN. INFO.:	GB 1985-6230		19860306
	GB 1985-11029		19850311
	GB 1986-2370		19850501
			19860131
REFERENCE PAT. INFO.:	EP 56782 A		

=>

L361 ANSWER 1 OF 5 USPATFULL
 ACCESSION NUMBER: 2001:224588 USPATFULL
 TITLE: Methods of using inhibitors of cyclophilin rotamase activity to affect neurological activity
 INVENTOR(S): Steiner, Joseph P., Finksburg, MD, United States
 Hamilton, Gregory S., Catonsville, MD, United States
 Snyder, Solomon H., Baltimore, MD, United States
 PATENT ASSIGNEE(S): Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
 Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6444643	B1	20020903
APPLICATION INFO.:	US 1999-321762		19990528 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-560685, filed on 20 Nov 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kunz, Gary L.		
ASSISTANT EXAMINER:	Gucker, Stephen		
LEGAL REPRESENTATIVE:	Howrey Simon Arnold & White, LLP		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	-		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	923		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the method of using neurotrophic cyclophilin inhibitor compounds having an affinity for cyclophilin-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L361 ANSWER 2 OF 5 USPATFULL
 ACCESSION NUMBER: 2001:102610 USPATFULL
 TITLE: Cyclosporin fermentation process
 INVENTOR(S): Ko, Soo Young, London, United Kingdom
 Kobel, Hans, Basel, Switzerland
 Besemer-Rosenwirth, Brigitte, Modling, Austria
 Seebach, Dieter, Zurich, Switzerland
 Traber, ReneP., Basel, Switzerland
 Wenger, Roland, Riehen, Switzerland
 Bollinger, Pietro, Bottmingen, Switzerland
 PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6255100	B1	20010703
APPLICATION INFO.:	US 1999-392282		19990909 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-84709, filed on 26 May 1998, now patented, Pat. No. US 5981479 Division of Ser. No. US 1995-427312, filed on 24 Apr 1995, now patented, Pat. No. US 5767069 Continuation of Ser. No. US 1994-232795, filed on 25 Apr 1994, now abandoned Continuation of Ser. No. US 1993-57067, filed on 3 May 1993, now abandoned Continuation of Ser. No. US 1991-785959, filed on 31 Oct 1991, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1990-23859	19901102
	GB 1990-23970	19901105

DOCUMENT TYPE:	Utility	13901105
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Wessendorf, T. D.	
LEGAL REPRESENTATIVE:	Lopez, Gabriel	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	809	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been found that nonimmunosuppressive, cyclophilin-binding **cyclosporins** are useful in the treatment and prevention of AIDS and AIDS-related disorders. Such **cyclosporins** include novel Cyclosporin derivatives modified at the 4- and/or 5-positions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L361 ANSWER 3 OF 5 USPATFULL

ACCESSION NUMBER:	1999:141886 USPATFULL
TITLE:	Cyclosporins
INVENTOR(S):	Ko, Soo Young, London, United Kingdom Kobel, Hans, Basel, Switzerland Besemer-Rosenwirth, Brigitte, Modling, Austria Seebach, Dieter, Zurich, Switzerland Traber, Rene P., Basel, Switzerland Wenger, Roland, Riehen, Switzerland Bollinger, Pietro, Bottmingen, Switzerland
PATENT ASSIGNEE(S):	Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5981479		19991109
APPLICATION INFO.:	US 1998-84709		19980536 (9)
RELATED APFLN. INFO.:	Division of Ser. No. US 1995-427312, filed on 24 Apr 1995, now patented, Pat. No. US 5767069		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1990-23859	19901102
	GB 1990-23970	19901105
	GB 1990-23971	19901105
	GB 1990-23972	19901105
	GB 1991-16836	19910805
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Tsang, Cecilia J.	
LEGAL REPRESENTATIVE:	Lopez, Gabriel, Furman, Diane E.	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	841	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been found that nonimmunosuppressive, cyclophilin-binding **cyclosporins** are useful in the treatment and prevention of AIDS and AIDS-related disorders. Such **cyclosporins** include novel Cyclosporin derivatives modified at the 4- and/or 5-positions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L361 ANSWER 4 OF 5 USPATFULL	
ACCESSION NUMBER:	1998:68992 USPATFULL
TITLE:	Cyclosporins
INVENTOR(S):	Ko, Soo Young, London, Great Britain

Kobel, Hans, Basel, Switzerland
Besemer-Rosenwirth, Brigitte, Modling, Austria
Seebach, Dieter, Zurich, Switzerland
Traber, Rene P., Basel, Switzerland
Wenger, Roland, Riehen, Switzerland
Bollinger, Pietro, Bottmingen, Switzerland
Novartis AG, Basel, Switzerland (non-U.S. corporation)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5767069		19980616
APPLICATION INFO.:	US 1995-427312		19950424 (3)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-232795, filed on 25 Apr 1994, now abandoned which is a continuation of Ser. No. US 1993-57067, filed on 3 May 1993, now abandoned which is a continuation of Ser. No. US 1991-785959, filed on 31 Oct 1991, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1990-13859	19901102
	GB 1990-23970	19901105
	GB 1990-23971	19901105
	GB 1990-23972	19901105
	GB 1991-16836	19910805
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Achutamurthy, Pennathapura	
ASSISTANT EXAMINER:	Wessendorf, T. D.	
LEGAL REPRESENTATIVE:	Mathias, Marla J., McGovern, Thomas O.	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	779	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Nonimmunosuppressant cyclosporin derivatives having cyclophilin-binding activity, for example, the compound, [Meile].sup.4 -ciclosporin, are useful in inhibiting HIV-1 replication in treating AIDS and AIDS related disorders.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L361 ANSWER 5 OF 5 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER:	484281	EUROPATFULL	EW 199319	FS OS STA B
TITLE:	Cyclosporins. Zyklosporine. Cyclosporines.			
INVENTOR(S):	Ko, Soo Young, Flat 5, 42 Belsize Park Gardens, London NW3 4LY, GB; Kobel, Hans, Weissensteinstrasse 1, CH-4059 Basle, CH; Rosenwirth, Brigitte, C. Zwillinggasse 17, A-2340 Moedling, AT; Seebach, Dieter, Orellistrasse 3, CH-8044 Zuerich, CH; Traber, Rene P., Hirzhoedenpark 20, CH-4052 Basle, CH; Wenger, Roland, Grenzacherweg 45, CH-4125 Riehen, CH; Bollinger, Pietro, Gustackerstrasse 56, CH-4103 Bottmingen, CH			
PATENT ASSIGNEE(S):	SANDOZ LTD., Lichtstrasse 35, CH-4002 Basel, CH, in BE, CH, DK, ES, FR, GB, GE, IT, LI, LU, NL, SE; SANDOZ-PATENT-GMBH, Humboldtstrasse 3, W-7850 Loerrach, DE, in DE; SANDOZ ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.,			

PATENT ASSIGNEE NO: Brunner Strasse 59, A-1235 Vienna, AT, in AT
 OTHER SOURCE: 201940; 498060; 1297990
 SOURCE: EPB1997009 EP 0484281 B1 970129
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veröffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
 PATENT INFO. PUB. TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT
 PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 484281	A2	19920506
'OFFENLEGUNGS' DATE:		19920506
APPLICATION INFO.:	EP 1991-810841	19911030
PRIORITY APPLN. INFO.:	GB 1990-23859	19901103
	GB 1990-23972	19901105
	GB 1990-23970	19901105
	GB 1990-23971	19901105
	GB 1991-16836	19910805

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 484281 EUROPATFULL EW 199705 FS PS
 TITLE: **Cyclosporins.**
 Inventor(s):
 Ko, See Young, Flat 5, 42 Belsize Park Gardens, London
 NW3 4LY, GB;
 Kobel, Hans, Weissensteinstrasse 1, CH-4059 Basle, CH;
 Rosenwirth, Brigitte, C. Zwillinggasse 17, A-2340
 Moedling, AT;
 Seebach, Dieter, Orellistrasse 3, CH-8044 Zuerich, CH;
 Traber, Pene P., Hirzbodenpark 20, CH-4052 Basle, CH;
 Wenger, Roland, Grenzacherweg 45, CH-4125 Riehen, CH;
 Bollinger, Pietro, Gustackerstrasse 56, CH-4103
 Bottmingen, CH
 PATENT ASSIGNEE(S): SANDOZ LTD., Lichtstrasse 35, 4002 Basel, CH, in BE, CH,
 DK, ES, FR, GB, GR, IT, LI, LU, NL, SE;
 SANDOZ-PATENT-GMBH, Humboldtstrasse 3, 79539 Loerrach,
 DE, in DE;
 SANDOZ ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.,
 Brunner Strasse 59, 1235 Wien, AT, in AT
 201940; 498060; 1297990
 PATENT ASSIGNEE NO: EPB1997009 EP 0484281 B1 970129
 OTHER SOURCE:
 SOURCE: Wila-EPS-1997-H05-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veröffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
 PATENT INFO. PUB. TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT
 PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 484281	B1	19970129
'OFFENLEGUNGS' DATE:		19920506
APPLICATION INFO.:	EP 1991-810841	19911030
PRIORITY APPLN. INFO.:	GB 1990-23859	19901103
	GB 1990-23972	19901105
	GB 1990-23970	19901105
	GB 1990-23971	19901105
	GB 1991-16836	19910805
REFERENCE PAT. INFO.:	EP 373360 A	GB 2227244 A
	US 4814323 A	

L361 ANSWER 1 OF 5 USPATFULL
ACCESSION NUMBER: 2002:224588 USPATFULL
TITLE: Methods of using inhibitors of cyclophilin rotamase activity to affect neurological activity
INVENTOR(S): Steiner, Joseph P., Finksburg, MD, United States
Hamilton, Gregory S., Catonsville, MD, United States
Snyder, Solomon H., Baltimore, MD, United States
PATENT ASSIGNEE(S): Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6444643	B1	20020903
APPLICATION INFO.:	US 1999-321762		19990528 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-560685, filed on 20 Nov 1995, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kunz, Gary L.
ASSISTANT EXAMINER: Gucker, Stephen
LEGAL REPRESENTATIVE: Howrey Simon Arnold & White, LLP
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 923

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the method of using neurotrophic cyclophilin inhibitor compounds having an affinity for cyclophilin-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> d 1261 1-5 ibib abs
L261 HAS NO ANSWERS
L1      QUE ABB=ON PLU=ON CYCLOSPORIN AND (SYNTHESIS OR SYNTHE
          SIZED)
L21      16 SEA FILE=IFIPAT ABB=ON PLU=ON L1 AND ALKYL
L201      0 SEA FILE=IFIPAT ABB=ON PLU=ON L21 AND (POSITION (W) 4 OR 4
          (W) POSITION)
L261      0 SEA FILE=IFIPAT ABB=ON PLU=ON L201 AND PHARMACEUTICAL
```

```
=> d 361 1-5 ibib abs
      5 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):1361
ANSWER NUMBERS NOT CORRECTLY SPECIFIED
Enter an answer number, Example: 10
several answer numbers, Example: 3,7,10
a range of answer numbers, Example: 5-10
or a combination of these. Example: 3,7,9-10,15
ENTER ANSWER NUMBER OR RANGE (1):
<-----User Break----->
```

```
ENTER ANSWER NUMBER OR RANGE (1):1361 1-5 ibib bas
ANSWER NUMBERS NOT CORRECTLY SPECIFIED
Enter an answer number, Example: 10
several answer numbers, Example: 3,7,10
a range of answer numbers, Example: 5-10
or a combination of these. Example: 3,7,9-10,15
ENTER ANSWER NUMBER OR RANGE (1):
```

<-----User Break----->

ENTER ANSWER NUMBER OR RANGE (1): d 1361 1-5 ibib bas

ANSWER NUMBERS NOT CORRECTLY SPECIFIED

Enter an answer number, Example: 10
several answer numbers, Example: 3,7,10
a range of answer numbers, Example: 5-10
or a combination of these. Example: 3,7,9-10,15

ENTER ANSWER NUMBER OR RANGE (1):all

ANSWER NUMBERS NOT CORRECTLY SPECIFIED

Enter an answer number, Example: 10
several answer numbers, Example: 3,7,10
a range of answer numbers, Example: 5-10
or a combination of these. Example: 3,7,9-10,15

ENTER ANSWER NUMBER OR RANGE (1):d 1361 all

ANSWER NUMBERS NOT CORRECTLY SPECIFIED

Enter an answer number, Example: 10
several answer numbers, Example: 3,7,10
a range of answer numbers, Example: 5-10
or a combination of these. Example: 3,7,9-10,15

ENTER ANSWER NUMBER OR RANGE (1):1-5

L361 ANSWER 1 OF 5 USPATFULL

ACCESSION NUMBER: 2002:224588 USPATFULL

TITLE: Methods of using inhibitors of cyclophilin rotamase activity to affect neurological activity

INVENTOR(S): Steiner, Joseph P., Finksburg, MD, United States
Hamilton, Gregory S., Catonsville, MD, United States
Snyder, Solomon H., Baltimore, MD, United States

PATENT ASSIGNEE(S): Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)

Johns Hopkins University School of Medicine, Baltimore,
MD, United States (U.S. corporation)

NUMBER KIND DATE

US 6444643 B1 20020903

US 1999-321762 19990528 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-560685, filed on 20 Nov 1995, now abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Kunz, Gary L.

ASSISTANT EXAMINER: Gucker, Stephen

LEGAL REPRESENTATIVE: Howrey Simon Arnold & White, LLP

NUMBER OF CLAIMS: 6

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)

LINE COUNT: 923

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the method of using neurotrophic cyclophilin inhibitor compounds having an affinity for cyclophilin-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L361 ANSWER 2 OF 5 USPATFULL

ACCESSION NUMBER: 2001:102610 USPATFULL

TITLE: Cyclosporin fermentation process

INVENTOR(S): Ko, Soo Young, London, United Kingdom

Kobel, Hans, Basel, Switzerland

Besemer-Rosenwirth, Brigitte, Modling, Austria

Seebach, Dieter, Zurich, Switzerland

Traber, ReneP., Basel, Switzerland

PATENT ASSIGNEE(S) : Wenger, Roland, Riehen, Switzerland
Bollinger, Pietro, Bottmingen, Switzerland
Novartis AG, Basel, Switzerland (non-U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.:
RELATED APPLN. INFO.:

NUMBER	KIND	DATE
US 6255100	B1	20010703
US 1999-392282		19990909 (9)
Division of Ser. No. US 1998-84709, filed on 26 May 1998, now patented, Pat. No. US 5981479 Division of Ser. No. US 1995-427312, filed on 24 Apr 1995, now patented, Pat. No. US 5767069 Continuation of Ser. No. US 1994-232795, filed on 25 Apr 1994, now abandoned Continuation of Ser. No. US 1993-57067, filed on 3 May 1993, now abandoned Continuation of Ser. No. US 1991-785959, filed on 31 Oct 1991, now abandoned		

PRIORITY INFORMATION:

NUMBER	DATE
GB 1990-23859	19901102
GB 1990-23970	19901105
GB 1990-23971	19901105
GB 1990-23972	19901105
GB 1991-16836	19910805

DOCUMENT TYPE:

Utility

FILE SEGMENT:

GRANTED

PRIMARY EXAMINER:

Wessendorf, T. D.

LEGAL REPRESENTATIVE:

Lopez, Gabriel

NUMBER OF CLAIMS:

3

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

3 Drawing Figure(s); 3 Drawing Page(s)

LINE COUNT:

809

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been found that nonimmunosuppressive, cyclophilin-binding **cyclosporins** are useful in the treatment and prevention of AIDS and AIDS-related disorders. Such **cyclosporins** include novel Ciclosporin derivatives modified at the 4- and/or 5-positions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L361 ANSWER 3 OF 5 USPATFULL

ACCESSION NUMBER:

1999:141886 USPATFULL

TITLE:

Cyclosporins

INVENTOR(S) :

Ko, Soo Young, London, United Kingdom

Kobel, Hans, Basel, Switzerland

Besemer-Rosenwirth, Brigitte, Modling, Austria

Seebach, Dieter, Zurich, Switzerland

Traber, Rene P., Basel, Switzerland

Wenger, Roland, Riehen, Switzerland

Bollinger, Pietro, Bottmingen, Switzerland

PATENT ASSIGNEE(S) : Novartis AG, Basel, Switzerland (non-U.S. corporation)

PATENT INFORMATION:

NUMBER	KIND	DATE
US 5981479		19991109

APPLICATION INFO.:

US 1998-84709		19980526 (9)
---------------	--	--------------

RELATED APPLN. INFO.:

Division of Ser. No. US 1995-427312, filed on 24 Apr 1995, now patented, Pat. No. US 5767069		
--	--	--

PRIORITY INFORMATION:

NUMBER	DATE
GB 1990-23859	19901102
GB 1990-23970	19901105
GB 1990-23971	19901105
GB 1990-23972	19901105
GB 1991-16836	19910805

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
LEGAL REPRESENTATIVE: Lopez, Gabriel, Furman, Diane E.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 841

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been found that nonimmunosuppressive, cyclophilin-binding **cyclosporins** are useful in the treatment and prevention of AIDS and AIDS-related disorders. Such **cyclosporins** include novel Ciclosporin derivatives modified at the 4- and/or 5-positions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L361 ANSWER 4 OF 5 USPATFULL

ACCESSION NUMBER: 1998:68992 USPATFULL

TITLE: **Cyclosporins**

INVENTOR(S): Ko, Soo Young, London, Great Britain
Kobel, Hans, Basel, Switzerland
Besemer-Rosenwirth, Brigitte, Modling, Austria
Seebach, Dieter, Zurich, Switzerland
Traber, Rene P., Basel, Switzerland
Wenger, Roland, Riehen, Switzerland
Bollinger, Pietro, Bottmingen, Switzerland
Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5767069		19980616
APPLICATION INFO.:	US 1995-427312		19950424 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-232795, filed on 25 Apr 1994, now abandoned which is a continuation of Ser. No. US 1993-57067, filed on 3 May 1993, now abandoned which is a continuation of Ser. No. US 1991-785959, filed on 31 Oct 1991, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1990-23859	19901102
	GB 1990-23970	19901105
	GB 1990-23971	19901105
	GB 1990-23972	19901105
	GB 1991-16836	19910805

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Achutamurthy, Ponnathapura
ASSISTANT EXAMINER: Wessendorf, T. D.
LEGAL REPRESENTATIVE: Mathias, Marla J., McGovern, Thomas O.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 779

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nonimmunosuppressant **cyclosporin** derivatives having cyclophilin-binding activity, for example, the compound, [MeIle].sup.4 -ciclosporin, are useful in inhibiting HIV-1 replication in treating AIDS and AIDS related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L361 ANSWER 5 OF 5 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 484281 EUROPATFULL EW 199219 FS OS STA B
 TITLE: **Cyclosporins.**
 INVENTOR(S): Ko, Soo Young, Flat 5, 42 Belsize Park Gardens, London NW3 4LY, GB;
 Kobel, Hans, Weissensteinstrasse 1, CH-4059 Basle, CH;
 Rosenwirth, Brigitte, C. Zwillinggasse 17, A-2340 Moedling, AT;
 Seebach, Dieter, Orellistrasse 3, CH-8044 Zuerich, CH;
 Traber, Rene P., Hirzbodenpark 20, CH-4052 Basle, CH;
 Wenger, Roland, Grenzacherweg 45, CH-4125 Riehen, CH;
 Bollinger, Pietro, Gustackerstrasse 56, CH-4103 Bottmingen, CH
 PATENT ASSIGNEE(S): SANDOZ LTD., Lichtstrasse 35, CH-4002 Basel, CH, in BE, CH, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE;
 SANDOZ-PATENT-GMBH, Humboldtstrasse 3, W-7850 Loerrach, DE, in DE;
 SANDOZ ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H., Brunner Strasse 59, A-1235 Vienna, AT, in AT 201940; 498060; 1297990
 PATENT ASSIGNEE NO: ESP1992035 EP 0484281 A2 920506
 OTHER SOURCE:
 SOURCE:
 DOCUMENT TYPE:
 LANGUAGE:
 DESIGNATED STATES: Anmeldung in Englisch; Veroeffentlichung in Englisch R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
 PATENT INFO. PUB. TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG
 PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 484281	A2	19920506
		19920506
EP 1991-810841		19911030
GB 1990-23859		19901102
GB 1990-23972		19901105
GB 1990-23970		19901105
GB 1990-23971		19901105
GB 1991-16836		19910805

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 484281 EUROPATFULL EW 199705 FS PS
 TITLE: **Cyclosporins.**
 INVENTOR(S): Ko, Soo Young, Flat 5, 42 Belsize Park Gardens, London NW3 4LY, GB;
 Kobel, Hans, Weissensteinstrasse 1, CH-4059 Basle, CH;
 Rosenwirth, Brigitte, C. Zwillinggasse 17, A-2340 Moedling, AT;
 Seebach, Dieter, Orellistrasse 3, CH-8044 Zuerich, CH;
 Traber, Rene P., Hirzbodenpark 20, CH-4052 Basle, CH;
 Wenger, Roland, Grenzacherweg 45, CH-4125 Riehen, CH;
 Bollinger, Pietro, Gustackerstrasse 56, CH-4103 Bottmingen, CH
 PATENT ASSIGNEE(S): SANDOZ LTD., Lichtstrasse 35, 4002 Basel, CH, in BE, CH, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE;
 SANDOZ-PATENT-GMBH, Humboldtstrasse 3, 79539 Loerrach, DE, in DE;
 SANDOZ ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H., Brunner Strasse 59, 1235 Wien, AT, in AT 201940; 498060; 1297990
 PATENT ASSIGNEE NO: EPB1997009 EP 0484281 B1 970129
 OTHER SOURCE:
 SOURCE:
 DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R
IT; R LI; R LU; R NL; R SE
PATENT INFO. PUB. TYPE: EPB1 EUROPÄISCHE PATENTSCHRIFT
PATENT INFORMATION:

	PATENT NO	KIND	DATE
'OFFENLEGUNGS' DATE:	EP 484281	B1	19970129
APPLICATION INFO.:	EP 1991-810841		19920506
PRIORITY APPLN. INFO.:	GB 1990-23859		19911030
	GB 1990-23972		19901102
	GB 1990-23970		19901105
	GB 1990-23971		19901105
	GB 1991-16836		19901105
REFERENCE PAT. INFO.:	EP 373260 A	GB 2227244 A	
	US 4814323 A		

=>